---
title: "Shanghai OPM Biosciences Co., Ltd. (688293.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688293.SH.md"
symbol: "688293.SH"
name: "Shanghai OPM Biosciences Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-21T13:49:07.466Z"
locales:
  - [en](https://longbridge.com/en/quote/688293.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688293.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688293.SH.md)
---

# Shanghai OPM Biosciences Co., Ltd. (688293.SH)

## Company Overview

Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed supplements, such as OPM's CHO-Platform, OPM-293 Platform, and VegaCHO media and feeds, as well as customized cell culture media development services. It also provides end-to-end biologics CDMO services, such as antibody discovery, stable cell line development, cell banking, upstream process development, downstream process development, formulation development, and quality control and product characterization of biologics.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.opmbiosciences.com](https://www.opmbiosciences.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: B (0.39)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 16 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 50.52% |  |
| Net Profit YoY | 310.49% |  |
| P/B Ratio | 2.18 |  |
| Dividend Ratio | 0.75% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6517909497.11 |  |
| Revenue | 452518182.66 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 2.73% | C |
| Profit Margin | 14.61% | B |
| Gross Margin | 43.79% | B |
| Revenue YoY | 50.52% | A |
| Net Profit YoY | 310.49% | A |
| Total Assets YoY | 87.27% | A |
| Net Assets YoY | 29.94% | A |
| Cash Flow Margin | 83.63% | C |
| OCF YoY | 50.52% | A |
| Turnover | 0.14 | E |
| Gearing Ratio | 36.53% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai OPM Biosciences Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "50.52%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "310.49%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.18",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.75%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6517909497.11",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "452518182.66",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "2.73%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "14.61%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "43.79%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "50.52%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "310.49%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "87.27%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "29.94%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "83.63%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "50.52%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.14",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "36.53%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 95.30 | 33/81 | 288.70 | 161.15 | 137.12 |
| PB | 2.11 | 30/81 | 3.06 | 2.79 | 2.33 |
| PS (TTM) | 13.93 | 62/81 | 19.96 | 18.03 | 16.10 |
| Dividend Yield | 0.77% | 25/81 | 0.87% | 0.77% | 0.72% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | Biocytogen (688796.SH) | A | A | E | B | A | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-26T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 45.34 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688293.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688293.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688293.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/688293.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**